Accessibility Menu
 
Hls Therapeutics logo

Hls Therapeutics

(TSX) HLS

Current Price$4.65
Market Cap$145.11M
Since IPO (2018)-57%
5 Year-75%
1 Year+10%
1 Month+6%

Hls Therapeutics Financials at a Glance

Market Cap

$145.11M

Revenue (TTM)

$55.73M

Net Income (TTM)

$12.45M

EPS (TTM)

$-0.55

P/E Ratio

-8.41

Dividend

$0.00

Beta (Volatility)

0.49 (Low)

Price

$4.65

Volume

7,500

Open

$4.63

Previous Close

$4.65

Daily Range

$4.55 - $4.71

52-Week Range

$4.22 - $5.76

HLS News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hls Therapeutics

Industry

Pharmaceuticals

Employees

85

CEO

Craig Millian, MBA

Headquarters

Etobicoke, ON M9W 6L2, CA

HLS Financials

Key Financial Metrics (TTM)

Gross Margin

72%

Operating Margin

-7%

Net Income Margin

-22%

Return on Equity

-19%

Return on Capital

-4%

Return on Assets

-9%

Earnings Yield

-11.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$145.11M

Shares Outstanding

31.27M

Volume

7.50K

Avg. Volume

9.74K

Financials (TTM)

Gross Profit

$24.01M

Operating Income

$4.18M

EBITDA

$18.02M

Operating Cash Flow

$16.02M

Capital Expenditure

$208.59K

Free Cash Flow

$15.81M

Cash & ST Invst.

$11.70M

Total Debt

$49.73M

Hls Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$15.43M

-0.7%

Gross Profit

$7.20M

-44.0%

Gross Margin

46.65%

N/A

Market Cap

$145.11M

N/A

Market Cap/Employee

$1.58M

N/A

Employees

92

N/A

Net Income

$1.36M

+55.2%

EBITDA

$5.79M

+20.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$38.03M

+22.4%

Accounts Receivable

$7.85M

+4.3%

Inventory

$8.12M

-10.3%

Long Term Debt

$44.92M

-26.6%

Short Term Debt

$4.81M

-9.0%

Return on Assets

-9.07%

N/A

Return on Invested Capital

-3.69%

N/A

Free Cash Flow

$6.41M

+100.8%

Operating Cash Flow

$6.44M

+101.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JUSH.CNJushi Holdings Inc.
$0.69-11.54%
HBP.TOHelix BioPharma Corp.
$2.02+6.88%
RX.VBioSyent Inc.
$14.50-2.36%
GRIN.CNGrown Rogue International Inc.
$0.49-1.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$84.52-0.01%
NOKNokia
$11.30+0.05%
POETPoet Technologies
$8.03+0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$60.74-0.03%

Questions About HLS

What is the current price of Hls Therapeutics?

Hls Therapeutics is trading at CA$4.65 per share.

What is the 52-week range for Hls Therapeutics?

Over the past 52 weeks, Hls Therapeutics has traded between CA$4.22 and CA$5.77.

How much debt does Hls Therapeutics have?

As of the most recent reporting period, Hls Therapeutics reported total debt of $68.29M.

How much cash does Hls Therapeutics have on hand?

Hls Therapeutics reported $16.07M in cash and cash equivalents in its most recent financial results.

What is Hls Therapeutics’s dividend yield?

Hls Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.